Calumet, Inc. (NASDAQ:CLMT - Get Free Report) was up 10.3% on Monday . The stock traded as high as $16.92 and last traded at $16.68. Approximately 742,120 shares traded hands during trading, a decline of 22% from the average daily volume of 953,859 shares. The stock had previously closed at $15.13.
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on CLMT shares. TD Cowen lowered Calumet from a "buy" rating to a "hold" rating and lowered their price objective for the company from $26.00 to $16.00 in a research note on Tuesday, March 4th. UBS Group upgraded Calumet from a "sell" rating to a "neutral" rating and decreased their price target for the company from $15.00 to $12.00 in a report on Monday, March 17th. Bank of America began coverage on Calumet in a research report on Tuesday, May 13th. They issued a "buy" rating and a $15.00 price target for the company. Wells Fargo & Company cut their price objective on shares of Calumet from $23.00 to $21.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 14th. Finally, The Goldman Sachs Group reduced their target price on shares of Calumet from $16.00 to $14.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $18.50.
View Our Latest Report on CLMT
Calumet Trading Down 2.7%
The stock has a 50 day moving average of $12.65 and a 200-day moving average of $15.21. The stock has a market capitalization of $1.42 billion, a P/E ratio of -4.11 and a beta of 0.91.
Calumet (NASDAQ:CLMT - Get Free Report) last issued its earnings results on Friday, May 9th. The oil and gas company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.62). The firm had revenue of $993.90 million for the quarter, compared to analysts' expectations of $899.62 million. The company's revenue for the quarter was down 1.2% on a year-over-year basis. During the same period in the prior year, the company earned ($0.51) earnings per share. Research analysts anticipate that Calumet, Inc. will post -3.02 EPS for the current year.
Insider Buying and Selling at Calumet
In other news, Director Jennifer Straumins sold 100,000 shares of the firm's stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $13.17, for a total transaction of $1,317,000.00. Following the transaction, the director now directly owns 1,084,589 shares of the company's stock, valued at approximately $14,284,037.13. This trade represents a 8.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Stephen P. Mawer sold 3,655 shares of the business's stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $12.88, for a total value of $47,076.40. Following the completion of the sale, the director now owns 287,307 shares of the company's stock, valued at $3,700,514.16. The trade was a 1.26% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 282,433 shares of company stock valued at $4,194,334 in the last three months. Company insiders own 4.07% of the company's stock.
About Calumet
(
Get Free Report)
Calumet, Inc engages in the manufacturing, formulating, and marketing of a diversified slate of specialty branded products and renewable fuels to customers across a broad range of consumer-facing and industrial markets. It operates through the following segments: Specialty Products & Solutions, Performance Brands, Montana/Renewables, and Corporate.
Featured Stories
Before you consider Calumet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Calumet wasn't on the list.
While Calumet currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.